Dzhintropin

Dzhintropin – recombinant somatotropic hormonal drug.

Structure and form of release of Dzhintropin

Dzhintropin release in the form of lyophilisate for preparation of solution for п / to introduction in dosages 4 ME and 10 ME, containing active ingredient – соматропин – in number of 1,33 mg and 3,33 mg respectively.

Auxiliary components of drug are sodium chloride, dihydrosodium phosphate, glycine and Mannitolum.

Dzhintropin release in bottles complete with the one-time syringe and solvent.

Pharmacological action of Dzhintropin

Dzhintropin – genetically engineered somatotropic hormone which promotes somatic and skeletal growth. Dzhintropin's use makes rather strong impact on metabolic processes of an organism. Drug stimulates growth of bones of a skeleton, influencing bone metabolism and plates of an epiphysis of tubular bones. Increases muscle bulk that contributes to normalization of structure of a body. At patients with a lack of a growth hormone and osteoporosis hormonal therapy contributes to normalization of density and mineral composition of bones.

According to the instruction, Dzhintropin also reduces the level of cholesterol and stimulates transportation of amino acids in cells and protein synthesis, influencing a profile of lipoproteids and lipids. Increases the size of cells of muscles, a thymus, liver, gonads, a thyroid gland and adrenal glands. Insulin release oppresses. Detains in an organism phosphorus, potassium and sodium. Increases physical endurance, muscular activity and body weight.

Indications to Dzhintropin's use

According to the instruction, Dzhintropin appoint to children at a growth inhibition because of insufficient development by a growth hormone organism, at Shereshevsky-Turner's syndrome, and also at a chronic renal failure (at reduced function of kidneys more, than to 50% of norm) in the pubertal period.

The adult Dzhintropin appoint at the acquired or inborn deficit of a growth hormone as replaceable treatment.

Contraindications

Dzhintropin is contraindicated in the following cases:

• the period of pregnancy and breastfeeding (in case of Dzhintropin's use by a breast it is reasonable to refuse feeding);
• active tumors of a brain;
• malignant new growths;
• hypersensitivity to a somatropin and additional components of drug;
• depressions (in particular after the undergone heart and abdominal cavity operations, at acute respiratory insufficiency).

According to reviews, Dzhintropin it is necessary to appoint with care at intracranial hypertensia, a diabetes mellitus, a hypothyroidism.

Route of administration of Dzhintropin and mode of dosing

According to the instruction, Dzhintropin enter п / to, slowly, not more often than once a day, as a rule, before going to bed. For prevention of emergence of a lipoatrophia it is necessary to change places of an injection periodically.

Contents of a bottle need to be dissolved in 1 ml of the solvent attached to drug. For this purpose solvent is gathered the syringe and entered into a bottle through a stopper. Mix before full dissolution (without sharp stirring). Ready solution can be stored at a temperature of 2-8 degrees no more than 14 days.

Dosages for patients are selected individually depending on expressiveness of a lack of a growth hormone, body weight and efficiency of use.

At insufficient development of a growth hormone at children the dosage makes 25-35 mg on weight kg a day. It is necessary to appoint treatment at earlier age and to continue up to puberty or before closing of region of growth of bones. At achievement of desirable result treatment can be stopped.

At a lack of a growth hormone at adult patients the initial dosage of Dzhintropin, according to the instruction, makes 0,15-0,3 mg a day, and in the subsequent it is increased for achievement of desirable effect.

At Shereshevsky-Turner's syndrome, and also at a chronic renal failure at children which is followed by a growth inhibition the recommended dosage makes 50 mkg on weight kg a day.

Overdose

The acute overdose by Dzhintropin, according to reviews, can lead at first to development of a hypoglycemia, and later to a hyperglycemia. In case of long overdose the symptoms characteristic of surplus of a growth hormone in an organism are noted: giantism, an acromegalia, a hypothyroidism, decrease in concentration of cortisol in blood serum.

In case of overdose administration of drug needs to be stopped and carried out symptomatic therapy.

Side effects

According to reviews, Dzhintropin can cause such side effects as increase in intracranial pressure, a hyperglycemia, depression of function of a thyroid gland, a femur head epiphysiolysis, leukemoid tests, a mialgiya, an arthralgia, a liquid delay in an organism with development of peripheral hypostases, a tunnel syndrome.

As a rule, all above-mentioned symptoms have dozozivisimy character and pass after correction of a dose.

Such allergic reactions as itch and skin rash are sometimes possible. Very seldom in an organism antibodies to drug can be formed that reduces its efficiency.

Local reactions to Dzhintropin's use can be the following: an itch, pain, a swelling, a hyperemia and a lipoatrophia in the place of an injection.

Dzhintropin's interaction with other medicines

The promoting effect of a somatropin on growth hormones is reduced by GKS.

Simultaneous treatment by other hormones (a gonadotrophin, estrogen, anabolic steroids, hormones of a thyroid gland) can influence efficiency of drug.

Storage conditions

Drug is stored in the dark place at a temperature of 2-8 degrees. It is longer not necessary to store ready solution 14 days. Dzhintropin treats drugs of a prescription issue with the recommended period of storage – 24 months.